129 related articles for article (PubMed ID: 1629387)
1. Predictive value of symptoms of atypical depression for differential drug treatment outcome.
McGrath PJ; Stewart JW; Harrison WM; Ocepek-Welikson K; Rabkin JG; Nunes EN; Wager SG; Tricamo E; Quitkin FM; Klein DF
J Clin Psychopharmacol; 1992 Jun; 12(3):197-202. PubMed ID: 1629387
[TBL] [Abstract][Full Text] [Related]
2. Chronic depression: response to placebo, imipramine, and phenelzine.
Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E
J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152
[TBL] [Abstract][Full Text] [Related]
3. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo.
Quitkin FM; Stewart JW; McGrath PJ; Tricamo E; Rabkin JG; Ocepek-Welikson K; Nunes E; Harrison W; Klein DF
Br J Psychiatry Suppl; 1993 Sep; (21):30-4. PubMed ID: 8217065
[TBL] [Abstract][Full Text] [Related]
4. Defining the boundaries of atypical depression.
Quitkin FM; Harrison W; Liebowitz M; McGrath P; Rabkin JG; Stewart J; Markowitz J
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):19-21. PubMed ID: 6376482
[TBL] [Abstract][Full Text] [Related]
5. An outpatient evaluation of phenelzine and imipramine.
Davidson J; Raft D; Pelton S
J Clin Psychiatry; 1987 Apr; 48(4):143-6. PubMed ID: 3549705
[TBL] [Abstract][Full Text] [Related]
6. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.
Quitkin FM; Stewart JW; McGrath PJ; Liebowitz MR; Harrison WM; Tricamo E; Klein DF; Rabkin JG; Markowitz JS; Wager SG
Am J Psychiatry; 1988 Mar; 145(3):306-11. PubMed ID: 3278631
[TBL] [Abstract][Full Text] [Related]
7. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors.
Thase ME; Frank E; Mallinger AG; Hamer T; Kupfer DJ
J Clin Psychiatry; 1992 Jan; 53(1):5-11. PubMed ID: 1737741
[TBL] [Abstract][Full Text] [Related]
8. Psychopharmacologic validation of atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Tricamo E; Markowitz JS; Klein DF
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):22-5. PubMed ID: 6376483
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission.
Stewart JW; Tricamo E; McGrath PJ; Quitkin FM
Am J Psychiatry; 1997 Jan; 154(1):31-6. PubMed ID: 8988955
[TBL] [Abstract][Full Text] [Related]
10. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
[TBL] [Abstract][Full Text] [Related]
11. A comparison of phenelzine and imipramine in depressed inpatients.
Davidson JR; McLeod MN; Turnbull CD; Miller RD
J Clin Psychiatry; 1981 Oct; 42(10):395-7. PubMed ID: 7026542
[TBL] [Abstract][Full Text] [Related]
12. [Impact of personality factors in depression].
Quitkin FM
Encephale; 1993 Aug; 19 Spec No 3():491-2. PubMed ID: 8299548
[TBL] [Abstract][Full Text] [Related]
13. Can mildly depressed outpatients with atypical depression benefit from antidepressants?
Stewart JW; McGrath PJ; Quitkin FM
Am J Psychiatry; 1992 May; 149(5):615-9. PubMed ID: 1575250
[TBL] [Abstract][Full Text] [Related]
14. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.
McGrath PJ; Stewart JW; Nunes EV; Ocepek-Welikson K; Rabkin JG; Quitkin FM; Klein DF
Am J Psychiatry; 1993 Jan; 150(1):118-23. PubMed ID: 8417553
[TBL] [Abstract][Full Text] [Related]
15. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.
Quitkin FM; McGrath PJ; Stewart JW; Harrison W; Wager SG; Nunes E; Rabkin JG; Tricamo E; Markowitz J; Klein DF
Arch Gen Psychiatry; 1989 Sep; 46(9):787-93. PubMed ID: 2673130
[TBL] [Abstract][Full Text] [Related]
16. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant.
McGrath PJ; Stewart JW; Nunes EN; Quitkin FM
J Clin Psychiatry; 1994 Aug; 55(8):336-9. PubMed ID: 8071301
[TBL] [Abstract][Full Text] [Related]
17. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.
Stewart JW; McGrath PJ; Quitkin FM; Harrison W; Markowitz J; Wager S; Leibowitz MR
Arch Gen Psychiatry; 1989 Dec; 46(12):1080-7. PubMed ID: 2686575
[TBL] [Abstract][Full Text] [Related]
18. The influence of panic attacks on response to phenelzine and amitriptyline in depressed outpatients.
Kayser A; Robinson DS; Yingling K; Howard DB; Corcella J; Laux D
J Clin Psychopharmacol; 1988 Aug; 8(4):246-53. PubMed ID: 3062042
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of imipramine in psychotic versus nonpsychotic depression.
Birkenhager TK; van den Broek WW; Mulder PG; Moleman P; Bruijn JA
J Clin Psychopharmacol; 2008 Apr; 28(2):166-70. PubMed ID: 18344726
[TBL] [Abstract][Full Text] [Related]
20. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.
Parsons B; Quitkin FM; McGrath PJ; Stewart JW; Tricamo E; Ocepek-Welikson K; Harrison W; Rabkin JG; Wager SG; Nunes E
Psychopharmacol Bull; 1989; 25(4):524-34. PubMed ID: 2698483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]